RxDoctor Payments Data

Arika Couch

Family · Knoxville, TNNPI 1679045470

Payments from drug & device makers

$15,706in general payments, 2019–2025

Across 656 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Seagen Inc.$1K
  • Johnson & Johnson$978
  • AstraZeneca$963
  • Merck$855
  • Lilly USA, LLC$699
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$11,81875%
  • Education$2,10913%
  • Other$1,78011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis83$3,117
Seagen Inc.34$1,003
Johnson & Johnson33$978
AstraZeneca(2 entities)50$963
Merck39$855
Lilly USA, LLC24$699
Incyte Corporation24$597
Daiichi Sankyo Inc.25$532
Astellas Pharma US Inc18$502
Amgen21$496
Pfizer23$441
E.r. Squibb & Sons, L.L.C.28$434
Regeneron Healthcare Solutions, Inc.16$416
Genentech USA, Inc.20$350
Gilead(2 entities)17$311
Takeda Pharmaceuticals U.S.A., Inc.15$286
Eisai Inc.14$249
Bayer14$245
Bristol Myers Squibb10$207
AbbVie10$199
Exelixis Inc.9$193
GSK10$193
Sanofi9$188
Puma Biotechnology, Inc.9$155
AVEO Pharmaceuticals, Inc.5$149
Mirati Therapeutics, Inc.4$133
EMD Serono, Inc.6$122
Myriad Genetic Laboratories, Inc.7$122
Ipsen Biopharmaceuticals, Inc5$101
Array Biopharma Inc5$100
Pharmacyclics LLC, An Abbvie Company6$99
Legend Biotech USA Inc.2$91
Karyopharm Therapeutics Inc.4$91
Novocure Inc.5$87
Tersera Therapeutics LLC4$82
Blueprint Medicines Corporation3$75
ADC Therapeutics America, Inc.3$64
Myovant Sciences Inc.3$63
Pharmacosmos Therapeutics Inc.3$59
Coherus Oncology, Inc.3$53
Boehringer Ingelheim3$53
Deciphera Pharmaceuticals Inc.2$51
Beigene USA, Inc.2$41
Agios Pharmaceuticals, Inc.2$38
Morphosys, US Inc.2$31
Pharmaessentia USA Corporation1$30
Springworks Therapeutics, Inc.1$24
Taiho Oncology, Inc.2$24
Genmab U.S., Inc.1$24
Helsinn Therapeutics (U.S.), Inc.1$23
Pharmaand GmbH1$21
TG Therapeutics, Inc.1$21
Sobi, Inc1$20
Rigel Pharmaceuticals, Inc.1$19
G1 Therapeutics, Inc.1$19
Azurity Pharmaceuticals, Inc.1$18
Geron Corporation1$17
EUSA Pharma (US) LLC1$16
Alnylam Pharmaceuticals Inc.1$16
Acceleron Pharma, Inc.1$16

How this compares

$15,706 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$524,431
Medicare patients
125
Services billed
22,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban19$16,987
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen102$2,645
Letrozole79$1,740
Oxycodone Hcl60$1,572
Megestrol Acetate12$598
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$523
Prochlorperazine Maleate31$520
Duloxetine Hcl24$429
Ondansetron OdtOndansetron42$418
Potassium Chloride31$364
Gabapentin42$349
Methylprednisolone37$326
Anastrozole30$313
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$286
Dexamethasone13$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$978$16,98719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →